An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

Phase 3

Completed

Conditions: Epilepsy
Partial Onset Seizures

Interventions: Drug: Levetiracetam (LEV)

Registration Number: NCT01506882

Lead Sponsor: UCB Japan Co. Ltd.

Brief Summary: The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in the LEV 1000 mg/day to 2000 mg/day group, in newly or recently diagnosed epilepsy subjects.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 71

Inclusion Criteria

Subject is male or female and aged ≥ 16 years at Visit 1
Subjects with newly or recently diagnosed Epilepsy having experienced unprovoked Partial Seizures (IA, IB, IC), that are classifiable according to the International League Against Epilepsy (ILAE) classification of Epileptic Seizures
Subjects with at least 2 unprovoked seizures separated by a minimum of 48 hours in the year prior to Visit 1, of which, at least 1 unprovoked seizure occurred in the 3 months prior to Visit 1
Minimum body weight of 40 kg at Visit 1

Exclusion Criteria

Subject has a history or presence of seizure types other than partial (IA, IB, IC)
Subject has an experience of any type of brain surgery in the consecutive 2 years prior to Visit 1
Subject has a history or presence of known Pseudo-Seizures
Subject has been treated for Epilepsy with any Antiepileptic Drug (AED) within the 6 months prior to Visit 1. However, acute and sub-acute seizure treatments are accepted for a maximum use of 2 weeks, if the treatments are stopped for the week prior to Visit 1
Subject has a known clinically significant acute or chronic illness, such as but not restricted to: cardiac, renal, hepatic dysfunction, endocrinological, or psychiatric illness, and that may impair reliable participation in the study or necessitate the use of medication not allowed by the protocol

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Levetiracetam 1000 mg/day to 2000 mg/day group	Levetiracetam (LEV)	Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day. The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.
Levetiracetam 3000 mg/day group	Levetiracetam (LEV)	Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period. They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period. The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period	From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period	A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.

Secondary Outcome Measures

Name	Time	Method
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period	From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period	Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.
Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group	During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year	Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.
Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group	During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year	Median time to withdrawal will be estimated from the Kaplan-Meier curve.
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period	From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period	A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period	From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period	Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.
Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group	During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year	Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.
Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group	During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year	Median time to withdrawal will be estimated from the Kaplan-Meier curve.

Trial Locations

Locations (27): 8
🇯🇵
Kagoshima, Japan
21
🇯🇵
Daito, Japan
33
🇯🇵
Asaka, Japan
20
🇯🇵
Kamakura, Japan
17
🇯🇵
Kawasaki, Japan
32
🇯🇵
Kyoto, Japan
7
🇯🇵
Ube, Japan
12
🇯🇵
Fujisawa, Japan
22
🇯🇵
Okayama, Japan
29
🇯🇵
Sapporo, Japan
5
🇯🇵
Nagoya Aichi, Japan
14
🇯🇵
Hamamatsu, Japan
3
🇯🇵
Kitakyusyu, Japan
27
🇯🇵
Osaka, Japan
13
🇯🇵
Saitama, Japan
4
🇯🇵
Nara, Japan
1
🇯🇵
Sakai, Japan
15
🇯🇵
Osaka, Japan
24
🇯🇵
Osakasayama, Japan
18
🇯🇵
Yamagata, Japan
9
🇯🇵
Kokubunji, Japan
2
🇯🇵
Toyonaka, Japan
19
🇯🇵
Aomori, Japan
11
🇯🇵
Himeji, Japan
30
🇯🇵
Hirosaki, Japan
26
🇯🇵
Kodaira, Japan
25
🇯🇵
Miyakonojo, Japan